IL7 and melanoma: A proportion of mice receiving melanoma vaccine co-expressing IL-21 and IL-7 developed vitiligo over time, which possibly suggested that breaking of topical peripheral tolerance to self-antigens, in this case melanocyte-associated antigens, could be achieved using this new vaccine formulation.